Neumora's big neuroscience plans head toward the Nasdaq in second PhIII biotech IPO pitch in 24 hours
The largely dormant biotech IPO market started sizzling Friday, with two Phase III drug developers sending in their pitches for Nasdaq debuts this fall.
After Friday’s closing bell, the neuroscience biotech Neumora submitted its paperwork to go public, a day after RayzeBio disclosed its plans by penciling in a $100 million offering. The two would join a little over a dozen biotechs to hit the Nasdaq this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.